I am a scientist interested in Cancer, Aging and Evolution and also in developing interesting investment ideas regarding biotechnology companies (small to mid-cap) with innovative products (Gene-therapy, monoclonal antibodies, CRISPR methods, protein degraders) which are not easily accessible and understood by non-specialized investors. I have 15 years of experience in top research institutions (Harvard University, Max-Planck Institute and Gulbenkian) with published work in major journals (Nature, PLoS, Cell press). Also, in the last 5 years I acquired experience in scientific based analysis of specific biotech and healthcare companies holding assets under FDA approval, through participating and leading Beacon VP, a Boston Harvard/MIT alumni based biotech investment club. I am currently implementing valuation tools for SMID companies (DCF and rNPV analysis) together with science based approaches to define the best investment strategies surrounding an asset in clinical development. Disclosure: I am associated with Beacon VP investments, however I agree to not comment on any SA content by BVP or cover any shared content.